PRJNA795909
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
RNA-seq and WGS data from venetoclax sensitive and resistant AML cell lines OCI-AML2, MV-4-11, and MOLM-13.